VasoMedical to Exhibit EECP® Therapy at the American Association of Cardiovascular and Pulmonary Rehabilitation Annual Meeting
EECP® Therapy to make impact at premier healthcare event for the cardiopulmonary rehabilitation community
Septemeber 18, 2013 - WESTBURY, N.Y. - VasoMedical, Inc. (“VasoMedical”) (OTC BB: VASO), a diversified medical technology company specializing in the design, manufacture and sale of medical devices for noninvasive cardiology including EECP® Therapy systems, the gold standard of ECP therapy, announced today that the Company will participate and exhibit at the American Association of Cardiovascular and Pulmonary Rehabilitation Annual Meeting (AACVPR) from October 3-5, 2013 in Nashville, Tenn.
The 28th edition of AACVPR will be held at the Gaylord Opryland Resort and Convention Center. Throughout the course of three days nearly 1,000 physicians, cardiovascular and pulmonary nurses, exercise physiologists, respiratory and physical therapists, behavioral scientists, registered dietitians, instructors and students and other allied health professionals involved in the day-to-day care of cardiovascular and/or pulmonary rehabilitation patients will take part in the Annual Meeting. During the AACVPR meeting, members of the cardiopulmonary community will be able to connect, share best practices and learn about the latest developments and trends in the industry.
“AACVPR is the premier healthcare event for the cardiopulmonary rehabilitation community and it provides an excellent opportunity for VasoMedical to share pertinent clinical information which supports the beneficial relationship between EECP® Therapy and Cardiac Rehabilitation for this specialized community of healthcare professionals from across the country,” said Larry Liebman, Vice President of Sales & Marketing at VasoMedical.
Liebman continued, “EECP® Therapy is a leading, FDA cleared noninvasive and outpatient treatment for patients experiencing angina or angina-like symptoms, which to date, has been severely underutilized as a treatment option. This is very similar to the underutilization of Cardiac Rehabilitation programs. We hope that spreading the word about the benefits of EECP® Therapy – from consistent improvement in patients' health to significant savings and reduced hospitalizations – will really get AACVPR attendees excited about how the use of EECP® Therapy can help generate more patients for their programs and reduce healthcare costs.”
VasoMedical will be located at Booth 630.
VasoMedical, Inc. is a diversified medical technology company specializing in the manufacture and sale of medical devices and in the domestic sale of diagnostic imaging products. The Company's main proprietary products are EECP® Therapy systems, the gold standard of ECP treatment. The Company operates through three wholly owned subsidiaries: VasoSolutions, VasoMedical Global and VasoHealthcare. VasoSolutions manages and coordinates the design, manufacture and sales of EECP® Therapy systems, and other medical equipment operations; VasoMedical Global operates the Company's China-based subsidiaries; and VasoHealthcare is the operating subsidiary for the exclusive sales representation of GE Healthcare diagnostic imaging products in certain market segments. Additional information is available on the Company's website at www.vasomedical.com
Except for historical information contained in this release, the matters discussed are forward-looking statements that involve risks and uncertainties. When used in this release, words such as “anticipates”, “believes”, “could”, “estimates”, “expects”, “may”, “plans”, “potential” and “intends” and similar expressions, as they relate to the Company or its management, identify forward-looking statements. Such forward-looking statements are based on the beliefs of the Company's management, as well as assumptions made by and information currently available to the Company's management. Among the factors that could cause actual results to differ materially are the following: the effect of business and economic conditions; the effect of the dramatic changes taking place in the healthcare environment; the impact of competitive procedures and products and their pricing; medical insurance reimbursement policies; unexpected manufacturing or supplier problems; unforeseen difficulties and delays in the conduct of clinical trials and other product development programs; the actions of regulatory authorities and third-party payers in the United States and overseas; uncertainties about the acceptance of a novel therapeutic modality by the medical community; continuation of the GEHC agreement; and the risk factors reported from time to time in the Company's SEC reports. The Company undertakes no obligation to update forward-looking statements as a result of future events or developments.